Domainex and Pharmidex Announce Drug Discovery Services Alliance
News Jan 29, 2010
Domainex Ltd and Pharmidex announced the formation of a strategic alliance, combining their expertise and technologies to provide the market with an integrated, high-quality drug discovery services platform.
The joint service offering will amalgamate Domainex’s LeadBuilder technology for hit-finding, as well as its highly-experienced medicinal chemistry team, with Pharmidex’s renowned expertise and in vitro and in vivo capabilities in drug metabolism and pharmacokinetics (DMPK).
Concordant with the established track records of both partners, the alliance will have a particular emphasis on tackling the most challenging of scientific problems, including novel or “difficult” drug targets.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE